FDA Gastroenterology and Urology Advisory panel members July 30 voted no confidence in the effectiveness and safety of EDAP TMS SA’s Ablatherm high intensity focused ultrasound thermal ablation device as a treatment for localized prostate cancer.
EDAP hopes to launch the product in the U.S. as an alternative to surgery, as it already does in Europe,...